Olezarsen Demonstrates 60% Reduction in Triglycerides in Landmark Trial
WASHINGTON, D.C. – A new investigational RNA-targeted therapy, olezarsen, has shown a remarkable 60% reduction in triglyceride levels in patients with severely elevated triglycerides, according to results from the Phase 3 Essence-TIMI 73b trial. The findings, unveiled today, offer a potential breakthrough for individuals at high risk of cardiovascular events due to hypertriglyceridemia.
The Essence-TIMI 73b trial, funded by Ionis Pharmaceuticals, enrolled patients with very high triglyceride levels (between 200 and 1500 mg/dL) despite being on standard-of-care treatments. Elevated triglycerides are a major risk factor for pancreatitis and cardiovascular disease, impacting millions worldwide. Current therapies frequently enough fall short of adequately controlling these levels,leaving a notable unmet medical need. Olezarsen works by targeting and reducing the production of a protein involved in triglyceride metabolism, offering a novel approach to lipid management.
Dr.Robert Bergmark, a researcher involved in the trial, has received grant support from Abbott Vascular, Amgen, AstraZeneca, Inari, Ionis, MedImmune, Pfizer and philips, and has served as a consultant for Abbott Vascular, Abiomed, Bain Life Sciences, Bolt, CSI, Endovascular Engineering, Shockwave, SpectraWAVE and Terumo. The full trial data is expected to inform future clinical guidelines and perhaps offer a new treatment option for patients struggling to manage their triglyceride levels and reduce their cardiovascular risk.
